Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1802

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 8
Chunk 1802
---
 subsequent events that would have required adjustment or disclosure in the consolidated
financial statements, other than the following:

Annual Meeting of Stockholders

On February 13, 2025, the Company held a special
meeting of its stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved several
proposals to amend the Company’s Charter. The stockholders approved the business combination (the “Business Combination”)
reflected by the Amended and Restated Business Combination Agreement, dated May 23, 2024, as amended on December 20, 2024 (the “Business
Combination Agreement”). The stockholders also approved to change Bellevue Life Sciences Acquisition Corp.’s name to “OSR,
Inc.” The stockholders also approved to increase the number of shares of preferred stock that can be issued from 1,000,000 shares
to 20,000,000 shares. The stockholders also approved to provide that directors may be removed by the affirmative vote of the holders of
at least 66 2/3% of the voting power instead of for cause and by the affirmative vote of holders of a majority of the voting power. The
stockholders also approved to eliminate the current limitations on the corporate opportunity doctrine. The stockholders also approved
to provide that the quorum required for stockholder meetings is the holders of one-third in voting power of then outstanding shares of
capital stock entitled to vote at the meeting instead of the holders of a majority in voting power of then outstanding shares of capital
stock entitled to vote at the meeting. The stockholders also approved to all other changes including eliminating certain provisions related
to special purpose acquisition companies that will no longer be relevant following the closing of the Business Combination. The stockholders
also approved to elect nine (9) individuals as directors of OSR, Inc. following the closing of the Business Combination until their respective
successors are duly elected and qualified. The stockholders also approved, for purposes of complying with the applicable listing rules
of the Nasdaq Stock Market LLC, the issuance of shares of OSR, Inc. common stock pursuant to the Business Combination Agreement in connection
with the Business Combination. In connection with the votes to approve the Adjournment Proposal, 57,821 shares of common stock
of the Company were tendered for redemption.

Sponsor Advances

On April 11, 2025 and April 14, 2025, the Sponsor transferred $30,478
and $